Mumbai Experience Center reflects Agilent’s continued commitment to India
Bharat Bhardwaj, Vice President, Asia Pacific, Agilent Technologies spoke to Viveka Roychowdhury on why Agilent has been…
Author
Viveka Roychowdhury
Midst global headwinds, CDSCO cracks down on GLP-1 gold rush
As pharma companies deal with price wars, increasing regulatory heat and a volatile geopolitical situation, navigating this…
Companies need to look at anti-counterfeiting solutions from the perspective of protecting revenue,…
Can you briefly explain ASPA’s evolution and how the anti‑counterfeiting ecosystem has changed?
ASPA as an organisation started…
Our approach is to combine localised production with global quality standards
What do you see as India’s role in the evolving global life sciences and biopharma value chain over the next decade?
India is…
Building India Pharma Inc’s innovation muscle
While we agree that “what got us here (an affordable generics powerhouse) will not get us there (a leader in pharma innovation)”,…
India-EU FTA offers new hope
The signing of the India-EU Free Trade Agreement after almost two decades of negotiations is being hailed as the ‘mother of all…
India at a jumping-off point in terms of commitment to global clinical studies
If you were to pick one or two trends in clinical trials and research in India in 2026, what would you be looking at? What are the…
Our goal is to help companies reduce cost per cubic meter of wastewater treatment
The pharma industry is considered one of the most polluting industries, not just in India, but across the world. Antibiotics have…
Odisha’s pharma pitch
The recently held Odisha Pharma Summit 2025, the state’s first dedicated summit focused on pharmaceuticals, medical devices, and…
We are cost-competitive and aligned with global ESG framework demands
The biologics sector is very dependent on single-use products and containment solutions. For example, the COVID pandemic exposed…